Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobenfy PET/MRI Study on Dopamine Transmission in Schizophrenia
NCT07423546Phase 2Recruiting
- Sponsor
- New York State Psychiatric Institute
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trospium in schizophrenia, schizoaffective disorder and schizophreniform disorder (3 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: [18F]DOPA relative uptake rate at 5 weeks. Started Jul 2026; status: recruiting.
02
Drugs
trospium
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT07423546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423546.